再発または難治性T細胞非ホジキンリンパ腫の参加者におけるKK2223の人間の最初の研究
再発または難治性T細胞非ホジキンリンパ腫の参加者におけるKK2223のフェーズ1、多施設、非盲検、非ランダム化、用量エスカレーションおよびバックフィル研究
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Kyowa Kirin, Inc.
- 電話番号:+1-609-919-1100
- メール:KKD.Clinical.82@kyowakirin.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- まだ募集していません
- City of Hope
-
主任研究者:
- Christina Poh
-
コンタクト:
- Christina Poh
- 電話番号:916-734-7131
- メール:cpoh@coh.org
-
Orange、California、アメリカ、92868
- まだ募集していません
- University of California, Irvine Medical Center - Hematology/Oncology
-
コンタクト:
- Lauren Pinter Brown
- 電話番号:7144568200
- メール:lpinterb@uci.edu
-
主任研究者:
- Lauren Pinter Brown
-
Stanford、California、アメリカ、94305
- 募集
- Stanford University School of Medicine
-
主任研究者:
- Youn Kim
-
コンタクト:
- Youn Kim
- 電話番号:650-723-7893
- メール:younkim@stanford.edu
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- まだ募集していません
- Moffit Cancer Center
-
コンタクト:
- Yumeng Zhang
- 電話番号:844-304-8636
- メール:yumeng.zhang@moffitt.org
-
主任研究者:
- Yumeng Zhang
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- まだ募集していません
- Emory University Medical Center
-
主任研究者:
- Pamela Allen
-
コンタクト:
- Pamela Allen
- 電話番号:404-778-2407
- メール:pallen5@emory.edu
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- まだ募集していません
- University of Iowa Health
-
主任研究者:
- Eric Mou
-
コンタクト:
- Eric Mou
- 電話番号:800-777-8442
- メール:eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- まだ募集していません
- Beth Israel Deaconess Medical Center - Research
-
コンタクト:
- Salvia Jain
- 電話番号:617-726-2000
- メール:salvia.jain@mgh.harvard.edu
-
主任研究者:
- Salvia Jain
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine - Oncology Hospital - Public
-
主任研究者:
- Neha Mehta Shah
-
コンタクト:
- Neha Mehta Shah
- 電話番号:314.273-8566
- メール:mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601-2105
- まだ募集していません
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
主任研究者:
- Tatyana Feldman
-
コンタクト:
- Tatyana Feldman
- 電話番号:551-996-5900
- メール:tatyana.feldman@hmhn.org
-
-
New York
-
New York、New York、アメリカ、10021-6007
- 募集
- Memorial Sloan Kettering Cancer Center
-
主任研究者:
- Jasmine Zain
-
コンタクト:
- Jasmine Zain
- 電話番号:212-639-3045
- メール:zainj1@mskcc.org
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- まだ募集していません
- University Hospitals Cleveland Medical Center
-
コンタクト:
- Kevin Cooper
- 電話番号:216-844-8200
- メール:kevin.cooper@uhhospitals.org
-
主任研究者:
- Kevin Cooper
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- まだ募集していません
- Oregon Health & Science University
-
コンタクト:
- Craig Okada
- 電話番号:503-494-8397
- メール:okadac@ohsu.edu
-
主任研究者:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- まだ募集していません
- University of Pennsylvania - Abramson Cancer Center
-
主任研究者:
- Stefan Barta
-
コンタクト:
- Stefan Barta
- 電話番号:215-728-2674
- メール:Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- The University of Texas - MD Anderson Cancer Center
-
主任研究者:
- Ranjit Nair
-
コンタクト:
- Ranjit Nair
- 電話番号:171-379-2860
- メール:rnair@mdanderson.org
-
-
-
-
-
Bergamo、イタリア、24127
- まだ募集していません
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
主任研究者:
- Giuseppe Gritti
-
コンタクト:
- Giuseppe Gritti
- 電話番号:39035269492
- メール:giuseppe_gritti@yahoo.it
-
Bologna、イタリア、40138
- まだ募集していません
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
コンタクト:
- Luigi Zinzani Pier
- 電話番号:390516363680
- メール:pierluigi.zinzani@unibo.it
-
主任研究者:
- Luigi Zinzani Pier
-
Torino、イタリア、10126
- まだ募集していません
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
コンタクト:
- Federica Cavallo
- 電話番号:390116334264
- メール:f.cavallo@unito.it
-
主任研究者:
- Federica Cavallo
-
-
Torino
-
Candiolo、Torino、イタリア、10060
- まだ募集していません
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
主任研究者:
- Umberto Vitolo
-
コンタクト:
- Umberto Vitolo
- 電話番号:390116335934
- メール:umberto.vitolo@ircc.it
-
-
-
-
-
Madrid、スペイン、28027
- まだ募集していません
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
コンタクト:
- Miguel Canales Albendea
- 電話番号:34917277116
- メール:macanales@unav.es
-
主任研究者:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona、Barcelona、スペイン、8036
- まだ募集していません
- Hospital Clinic De Barcelona - Hematología
-
主任研究者:
- Pablo Mozas
-
コンタクト:
- Pablo Mozas
- 電話番号:34 93 227 22 71
- メール:mozas@clinic.cat
-
L'Hospitalet de Llobregat、Barcelona、スペイン、8907
- まだ募集していません
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
主任研究者:
- Eva Domingo Domenech
-
コンタクト:
- Eva Domingo Domenech
- 電話番号:34932607822
- メール:edomingo@iconcologia.net
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- まだ募集していません
- Clinica Universidad de Navarra - Hematología
-
コンタクト:
- Miguel Canales Albendea
- 電話番号:34917277116
- メール:macanales@unav.es
-
主任研究者:
- Miguel Canales Albendea
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
実験的:Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
時間枠:Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean Blood Drug Concentration
時間枠:Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
時間枠:Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
時間枠:Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
時間枠:Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
時間枠:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
時間枠:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
時間枠:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
時間枠:Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
時間枠:Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
時間枠:Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
時間枠:Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
時間枠:Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
時間枠:Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2223-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。